Teriparatide for treatment of osteoporosis in men aged over 50 years


Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing.

The aim of this evaluation report is to review the evidence for the efficacy, safety, and tolerability of teriparatide for use in male patients for osteoporosis treatment.

Drugs affecting bone metabolism


This report looks at prescribing trends in primary care for Drugs affecting bone metabolism at CCG and STP level with selected substances analysed at presentation level and also explores associations between prescribing and hospital admissions relating to hip fractures.

If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net



Data Period

April 2018 to March 2021

This report has been discontinued. If you would like an updated version of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net